Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

171 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Appendectomy is more frequent but not a risk factor in Crohn's disease while being protective in ulcerative colitis: a comparison of surgical procedures in inflammatory bowel disease.
Reif S, Lavy A, Keter D, Broide E, Niv Y, Halak A, Ron Y, Eliakim R, Odes S, Patz J, Fich A, Villa Y, Arber N, Gilat T. Reif S, et al. Among authors: ron y. Am J Gastroenterol. 2001 Mar;96(3):829-32. doi: 10.1111/j.1572-0241.2001.03529.x. Am J Gastroenterol. 2001. PMID: 11280559
The decline of anti-drug antibody titres after discontinuation of anti-TNFs: implications for predicting re-induction outcome in IBD.
Ben-Horin S, Mazor Y, Yanai H, Ron Y, Kopylov U, Yavzori M, Picard O, Fudim E, Maor Y, Lahat A, Coscas D, Eliakim R, Dotan I, Chowers Y. Ben-Horin S, et al. Among authors: ron y. Aliment Pharmacol Ther. 2012 Mar;35(6):714-22. doi: 10.1111/j.1365-2036.2012.04997.x. Epub 2012 Jan 30. Aliment Pharmacol Ther. 2012. PMID: 22288419
Induction infliximab levels among patients with acute severe ulcerative colitis compared with patients with moderately severe ulcerative colitis.
Ungar B, Mazor Y, Weisshof R, Yanai H, Ron Y, Goren I, Waizbard A, Yavzori M, Fudim E, Picard O, Loebstein R, Kopylov U, Dotan I, Chowers Y, Eliakim R, Ben-Horin S. Ungar B, et al. Among authors: ron y. Aliment Pharmacol Ther. 2016 Jun;43(12):1293-9. doi: 10.1111/apt.13631. Epub 2016 Apr 19. Aliment Pharmacol Ther. 2016. PMID: 27091119
Efficacy and Safety of Vedolizumab for Induction of Remission in Inflammatory Bowel Disease-the Israeli Real-World Experience.
Kopylov U, Ron Y, Avni-Biron I, Koslowsky B, Waterman M, Daher S, Ungar B, Yanai H, Maharshak N, Ben-Bassat O, Lichtenstein L, Bar-Gil Shitrit A, Israeli E, Schwartz D, Zittan E, Eliakim R, Chowers Y, Ben-Horin S, Dotan I. Kopylov U, et al. Among authors: ron y. Inflamm Bowel Dis. 2017 Mar;23(3):404-408. doi: 10.1097/MIB.0000000000001039. Inflamm Bowel Dis. 2017. PMID: 28178003
Effectiveness and safety of vedolizumab for maintenance treatment in inflammatory bowel disease-The Israeli real world experience.
Kopylov U, Avni-Biron I, Ron Y, Koslowsky B, Waterman M, Daher S, Ungar B, Schwartz D, Zittan E, Openhaim M, Yanai H, Maharshak N, Bar Gil Shitrit A, Naftali T, Eliakim R, Chowers Y, Ben-Horin S, Dotan I. Kopylov U, et al. Among authors: ron y. Dig Liver Dis. 2019 Jan;51(1):68-74. doi: 10.1016/j.dld.2018.07.040. Epub 2018 Aug 10. Dig Liver Dis. 2019. PMID: 30172649 Clinical Trial.
171 results